Abstract
Of the around 7,000 known rare diseases worldwide, disease-modifying treatments are available for fewer than 5%, leaving millions of individuals without specialized therapeutic strategies. In recent years, antisense oligonucleotides (ASOs) have shown promise as individualized genetic interventions for rare genetic diseases. However, there is currently no consensus on which disease-causing DNA variants are suitable candidates for this type of genetic therapy. The Patient Identification Working Group of the N=1 Collaborative (N1C), alongside an international group of volunteer assessors, has developed and piloted consensus guidelines for assessing the eligibility of pathogenic variants towards ASO treatments. We herein present the N1C VARIANT (Variant Assessments towards Eligibility for Antisense Oligonucleotide Treatment) guidelines, including the guiding scientific principles and our approach to consensus building. Pathogenic, disease-causing variants can be assessed for the three currently best-established ASO treatment approaches: splice correction, exon skipping, and downregulation of RNA transcripts. A genetic variant is classified as either “eligible”, “likely eligible”, “unlikely eligible”, or “not eligible” in relation to the different approaches, or “unable to assess”. We also review key considerations for assessment for upregulation of transcripts from the wildtype allele, an emerging ASO therapeutic strategy. We provide additional tools and training material to enable clinicians and researchers to use these guidelines for their eligibility assessments. With this initial edition of our N1C VARIANT guidelines, we provide the rare genetic disease community with guidance on how to identify suitable candidates for variant-specific ASO-based therapies and the possibility of integrating such assessments into routine clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the European Union, project European Rare Disease Research Alliance (ERDERA, # 101156595) (to M.S. and A.A.-R.). D.C. is supported by a SickKids Restracomp Master's Scholarship and the SickKids Innovators Fund. L.N. is supported by a Canada Graduate Scholarship - Master's from the Canadian Institutes of Health Research (CIHR). D.C., B.H., and G.C. also acknowledge support from CIHR (PJT186240). D.B. is supported by a Humboldt Research Fellowship and the Hertie-Network of Excellence in Clinical Neuroscience. M.C.L is funded by a Walter Benjamin Fellowship from the DFG. A.E.D, K.-A.M, and M.R. are supported by the UK Platform for Nucleic Acid Therapies (UpNAT). B.Z., A.A.-R., R.L. are supported by a ZonMW PSIDER grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available data from the ClinVar database: https://www.ncbi.nlm.nih.gov/clinvar/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available in supplementary files 2, 3, and 4 for variant assessments and upregulation from the WT allele approaches. All code was deployed on GitHub under an open-source AGPL license (https://github.com/N1Collaborative/Variant-Eligibility-Calculator).
https://github.com/N1Collaborative/Variant-Eligibility-Calculator
http://eligibilitycalculator.n1collaborative.org/
https://www.youtube.com/playlist?list=PL1FIwS0tbJHj0-aDMmZ5fUy5d40eiwa8B
